Gynecologic care for women with human immunodeficiency virus

Obstetrics and Gynecology

Volumn 116, Issue 6, 2010, Pages 1492-1509

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATAZANAVIR; COPPER INTRAUTERINE DEVICE; EFAVIRENZ; ETHINYLESTRADIOL; FOSAMPRENAVIR; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; INDINAVIR; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NELFINAVIR; NEVIRAPINE; ORAL CONTRACEPTIVE AGENT; RITONAVIR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CANCER INVASION; CANCER SCREENING; CANDIDA ALBICANS; CANDIDIASIS; CD4 LYMPHOCYTE COUNT; COCCIDIOIDOMYCOSIS; CONTRACEPTION; CRYPTOCOCCOSIS; CRYPTOSPORIDIOSIS; CYTOMEGALOVIRUS INFECTION; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; FAMILY PLANNING; FUNGAL COLONIZATION; GYNECOLOGIC CARE; HEALTH CARE PERSONNEL; HERPES SIMPLEX; HETEROSEXUALITY; HIGH RISK BEHAVIOR; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IMMUNOFLUORESCENCE TEST; INTRAUTERINE CONTRACEPTIVE DEVICE; ISOSPORIASIS; KAPOSI SARCOMA; LABORATORY DIAGNOSIS; LIVER TOXICITY; LYMPHOMA; MATERNAL CARE; MATERNAL WELFARE; MENOPAUSAL SYNDROME; MENSTRUATION DISORDER; MYCOBACTERIUM INTRACELLULARE AVIUM; PAPILLOMAVIRUS INFECTION; PATIENT COUNSELING; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RECURRENT INFECTION; SALMONELLOSIS; SCREENING; SEPTICEMIA; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE; SINGLE DRUG DOSE; TERATOGENICITY; TOXOPLASMOSIS; TUBERCULOSIS; UNITED STATES; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; VAGINA CANDIDIASIS; VAGINITIS; VIRUS TRANSMISSION; WASTING SYNDROME; WESTERN BLOTTING; WOMEN'S HEALTH;

EID: 79959369050     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3182054cae     Document Type: Article

References (137)

1. Centers for Disease Control and Prevention. HIV surveillance report: diagnoses of HIV infection and AIDS in the United States and dependent areas, 2008. Vol. 20. Atlanta (GA): CDC; 2010. Available at: http://www.cdc. gov/hiv/surveillance/resources/reports/2008report/pdf/2008SurveillanceReport. pdf. Retrieved June 17, 2010. (Level II-3)
2. Human immunodeficiency virus and acquired immunodeficiency syndrome and women of color. American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 414. Obstet Gynecol 2008;112:413-6. (Level III)
3. Kitahata MM, Koepsell TD, Deyo RA, Maxwell CL, Dodge WT, Wagner EH. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J Med 1996;334:701-6. (Level II-3) (Pubitemid 26079805)
4. Laine C, Markson LE, McKee LJ, Hauck WW, Fanning TR, Turner BJ. The relationship of clinic experience with advanced HIV and survival of women with AIDS. AIDS 1998;12:417-24. (Level II-3) (Pubitemid 28077539)
5. Anderson JR. Approach to the patient. In: Anderson JR, editor. A guide to the clinical care of women with HIV. Rockville (MD): Health Resources and Services Administration; 2005. p. 35-46. (Level III)
6. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Bethesda (MD): Department of Health and Human Services; 2009. Available at: http://www.aidsifo.nih.gov/ContentFiles/Adultand AdolescentGL.pdf. Retrieved June 17, 2010. (Level III)
7. Chersich MF, Urban MF, Venter FW, Wessels T, Krause A, Gray GE, et al. Efavirenz use during pregnancy and for women of child-bearing potential. AIDS Res Ther 2006;3:11. (Level III)
8. Routine human immunodeficiency virus screening. American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 411. Obstet Gynecol 2008;111:1495-502. (Level III)
9. Campsmith ML, Rhodes PH, Hall HI, Green TA. Undiagnosed HIV prevalence among adults and adolescents in the United States at the end of 2006 [published erratum appears in J Acquir Immune Defic Syndr 2010;54:112]. J Acquir Immune Defic Syndr 2010;53:619-24. (Level II-3)
10. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS 2006;20:1447-50. (Level III) (Pubitemid 43948252)
11. Marks G, Crepaz N, Senterfitt JW, Janssen RS. Metaanalysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr 2005;39:446-53. (Meta-analysis) (Pubitemid 41003791)
12. Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. Centers for Disease Control and Prevention (CDC). MMWR Recomm Rep 2006;55(RR-14):1-17; quiz CE1-4. (Level III)
13. Carey MP, Coury-Doniger P, Senn TE, Vanable PA, Urban MA. Improving HIV rapid testing rates among STD clinic patients: a randomized controlled trial. Health Psychol 2008;27:833-8. (Level I)
14. Iweala OI. HIV diagnostic tests: an overview. Contraception 2004;70:141-7. (Level III) (Pubitemid 38993490)
15. Update: HIV counseling and testing using rapid tests-United States, 1995. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep 1998;47:211-5. (Level III)
16. Greenwald JL, Burstein GR, Pincus J, Branson B. A rapid review of rapid HIV antibody tests. Curr Infect Dis Rep 2006;8:125-31. (Level III)
17. Kendrick SR, Kroc KA, Withum D, Rydman RJ, Branson BM, Weinstein RA. Outcomes of offering rapid point-ofcare HIV testing in a sexually transmitted disease clinic. J Acquir Immune Defic Syndr 2005;38:142-6. (Level III) (Pubitemid 40189320)
18. Franco-Paredes C, Tellez I, del Rio C. Rapid HIV testing: a review of the literature and implications for the clinician. Curr HIV/AIDS Rep 2006;3:169-75. (Level III) (Pubitemid 44657375)
19. Ellerbrock TV, Chiasson MA, Bush TJ, Sun XW, Sawo D, Brudney K, et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000;283:1031-7. (Level II-2) (Pubitemid 30112217)
20. Hawes SE, Critchlow CW, Faye Niang MA, Diouf MB, Diop A, Toure P, et al. Increased risk of high-grade cervical squamous intraepithelial lesions and invasive cervical cancer among African women with human immunodeficiency virus type 1 and 2 infections. J Infect Dis 2003;188:555-63. (Level II-3) (Pubitemid 37011808)
21. Schuman P, Ohmit SE, Klein RS, Duerr A, Cu-Uvin S, Jamieson DJ, et al. Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. HIV Epidemiology Research Study (HERS) Group. J Infect Dis 2003;188:128-36. (Level II-2) (Pubitemid 36829752)
22. Massad LS, Ahdieh L, Benning L, Minkoff H, Greenblatt RM, Watts H, et al. Evolution of cervical abnormalities among women with HIV-1: evidence from surveillance cytology in the women's interagency HIV study. J Acquir Immune Defic Syndr 2001;27:432-42. (Level II-2) (Pubitemid 32801071)
23. De Vuyst H, Lillo F, Broutet N, Smith JS. HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. Eur J Cancer Prev 2008;17:545-54. (Level III)
24. Massad LS, Evans CT, Minkoff H, Watts DH, Strickler HD, Darragh T, et al. Natural history of grade 1 cervical intraepithelial neoplasia in women with human immunodeficiency virus. Obstet Gynecol 2004;104:1077-85. (Level II-2) (Pubitemid 40458776)
25. Massad LS, Seaberg EC, Watts DH, Minkoff H, Levine AM, Henry D, et al. Long-term incidence of cervical cancer in women with human immunodeficiency virus. Cancer 2009;115:524-30. Level II-3)
26. Cervical cytology screening. ACOG Practice Bulletin No. 109. American College of Obstetricians and Gynecologists. Obstet Gynecol 2009;114:1409-20. (Level III)
27. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009;58(RR-4):1-207; quiz CE1-4. (Level III)
28. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference. Am J Obstet Gynecol 2007;197:346-55. (Level III) (Pubitemid 47464164)
29. Massad LS, Schneider MF, Watts DH, Strickler HD, Melnick S, Palefsky J, et al. HPV testing for triage of HIV-infected women with papanicolaou smears read as atypical squamous cells of uncertain significance. J Womens Health 2004;13:147-53. (Level II-3) (Pubitemid 38444314)
30. Kirby TO, Allen ME, Alvarez RD, Hoesley CJ, Huh WK. High-risk human papillomavirus and cervical intraepithelial neoplasia at time of atypical squamous cells of undetermined significance cytologic results in a population with human immunodeficiency virus. J Low Genit Tract Dis 2004;8:298-303. (Level II-2) (Pubitemid 39332205)
31. Boardman LA, Cotter K, Raker C, Cu-Uvin S. Cervical intraepithelial neoplasia grade 2 or worse in human immunodeficiency virus-infected women with mildly abnormal cervical cytology. Obstet Gynecol 2008;112:238-43. (Level II-3)
32. Massad LS, Evans CT, Strickler HD, Burk RD, Watts DH, Cashin L, et al. Outcome after negative colposcopy among human immunodeficiency virus-infected women with borderline cytologic abnormalities. Obstet Gynecol 2005;106:525-32. (Level II-2) (Pubitemid 41208784)
33. Massad LS, Seaberg EC, Watts DH, Hessol NA, Melnick S, Bitterman P, et al. Low incidence of invasive cervical cancer among HIV-infected US women in a prevention program. AIDS 2004;18:109-13. (Level II-2) (Pubitemid 38402324)
34. Lima MI, Tafuri A, Araujo AC, de Miranda Lima L, Melo VH. Cervical intraepithelial neoplasia recurrence after conization in HIV-positive and HIV-negative women. Int J Gynaecol Obstet 2009;104:100-4. (Level II-2)
35. Grinsztejn B, Veloso VG, Levi JE, Velasque L, Luz PM, Friedman RK, et al. Factors associated with increased prevalence of human papillomavirus infection in a cohort of HIV-infected Brazilian women [published erratum appears in Int J Infect Dis 2009;13:655-6]. Int J Infect Dis 2009;13:72-80. (Level II-3)
36. Holcomb K, Matthews RP, Chapman JE, Abulafia O, Lee YC, Borges A, et al. The efficacy of cervical conization in the treatment of cervical intraepithelial neoplasia in HIV-positive women. Gynecol Oncol 1999;74:428-31. (Level II-3) (Pubitemid 29439884)
37. Gingelmaier A, Grubert T, Kaestner R, Mylonas I, Weissenbacher T, Bergauer F, et al. High recurrence rate of cervical dysplasia and persistence of HPV infection in HIV-1-infected women. Anticancer Res 2007;27:1795-8. (Level II-3) (Pubitemid 46954678)
38. Massad LS, Fazzari MJ, Anastos K, Klein RS, Minkoff H, Jamieson DJ, et al. Outcomes after treatment of cervical intraepithelial neoplasia among women with HIV. J Low Genit Tract Dis 2007;11:90-7. (Level II-2) (Pubitemid 46597702)
39. Wright TC Jr, Subbarao S, Ellerbrock TV, Lennox JL, Evans-Strickfaden T, Smith DG, et al. Human immunodeficiency virus 1 expression in the female genital tract in association with cervical inflammation and ulceration. Am J Obstet Gynecol 2001;184:279-85. (Level III) (Pubitemid 32206972)
40. Paramsothy P, Duerr A, Heilig CM, Cu-Uvin S, Anderson JR, Schuman P, et al. Abnormal vaginal cytology in HIV-infected and at-risk women after hysterectomy. HIV Epidemiology Research (HER) Study Group. J Acquir Immune Defic Syndr 2004;35:484-91. (Level II-2) (Pubitemid 38420657)
41. Conley LJ, Ellerbrock TV, Bush TJ, Chiasson MA, Sawo D, Wright TC. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet 2002;359:108-13. (Level II-2) (Pubitemid 34112538)
42. Jamieson DJ, Paramsothy P, Cu-Uvin S, Duerr A. Vulvar, vaginal, and perianal intraepithelial neoplasia in women with or at risk for human immunodeficiency virus. HIV Epidemiology Research Study Group. Obstet Gynecol 2006;107:1023-8. (Level II-2)
43. Hessol NA, Holly EA, Efird JT, Minkoff H, Schowalter K, Darragh TM, et al. Anal intraepithelial neoplasia in a multisite study of HIV-infected and high-risk HIVuninfected women. AIDS 2009;23:59-70. (Level II-3)
44. Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Palefsky JM. Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men. Am J Med 2000;108:634-41. (Level III) (Pubitemid 30336603)
45. Aberg JA, Kaplan JE, Libman H, Emmanuel P, Anderson JR, Stone VE, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2009;49:651-81. (Level III)
46. Massad LS, Evans CT, D'Souza G, Darragh T, Minkoff H, Henry D, et al. High-grade cervical disease in adolescents with HIV. J Low Genit Tract Dis 2008;12:199-203. (Level II-3)
47. Moscicki AB, Ellenberg JH, Crowley-Nowick P, Darragh TM, Xu J, Fahrat S. Risk of high-grade squamous intraepithelial lesion in HIV-infected adolescents. J Infect Dis 2004;190:1413-21. (Level II-3) (Pubitemid 39332180)
48. Holcomb K, Matthews RP, Chapman JE, Abulafia O, Lee YC, Borges A, et al. The efficacy of cervical conization in the treatment of cervical intraepithelial neoplasia in HIV-positive women. Gynecol Oncol 1999;74:428-31. (Level II-3) (Pubitemid 29439884)
49. Williams SF, Keane-Tarchichi MH, Bettica L, Dieudonne A, Bardeguez AD. Pregnancy outcomes in young women with perinatally acquired human immunodeficiency virus-1. Am J Obstet Gynecol 2009;200:149.e1-149.e5. (Level III)
50. Cervical cancer in adolescents: screening, evaluation, and management. Committee Opinion No. 463. American College of Obstetricians and Gynecologists. Obstet Gynecol 2010;116;462-72. (Level III)
51. Levin MJ, Moscicki AB, Song LY, Fenton T, Meyer WA 3rd, Read JS, et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. IMPAACT P1047 Protocol Team. J Acquir Immune Defic Syndr 2010;55:197-204. (Level I)
52. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56(RR-2):1-24. (Level III)
53. Human papillomavirus vaccination. Committee Opinion No. 467. American College of Obstetricians and Gynecologists. Obstet Gynecol 2010;116;800-3. (Level III)
54. Watts DH, Springer G, Minkoff H, Hillier SL, Jacobson L, Moxley M, et al. The occurrence of vaginal infections among HIV-infected and high-risk HIV-uninfected women: longitudinal findings of the women's interagency HIV study. J Acquir Immune Defic Syndr 2006;43:161-8. (Level II-2) (Pubitemid 44454809)
55. Warren D, Klein RS, Sobel J, Kieke B Jr, Brown W, Schuman P, et al. A multicenter study of bacterial vaginosis in women with or at risk for human immunodeficiency virus infection. HIV Epidemiology Research Study Group. Infect Dis Obstet Gynecol 2001;9:133-41. (Level II-3) (Pubitemid 32737639)
56. Jamieson DJ, Duerr A, Klein RS, Paramsothy P, Brown W, Cu-Uvin S, et al. Longitudinal analysis of bacterial vaginosis: findings from the HIV epidemiology research study. Obstet Gynecol 2001;98:656-63. (Level II-2) (Pubitemid 32907463)
57. Ohmit SE, Sobel JD, Schuman P, Duerr A, Mayer K, Rompalo A, et al. Longitudinal study of mucosal Candida species colonization and candidiasis among human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. HIV Epidemiology Research Study (HERS) Group. J Infect Dis 2003;188:118-27. (Level II-2) (Pubitemid 36829751)
58. Duerr A, Sierra MF, Feldman J, Clarke LM, Ehrlich I, DeHovitz J. Immune compromise and prevalence of Candida vulvovaginitis in human immunodeficiency virus-infected women. Obstet Gynecol 1997;90:252-6. (Level II-3) (Pubitemid 27318843)
59. Duerr A, Heilig CM, Meikle SF, Cu-Uvin S, Klein RS, Rompalo A, et al. Incident and persistent vulvovaginal candidiasis among human immunodeficiency virusinfected women: Risk factors and severity. HER Study Group. Obstet Gynecol 2003;101:548-56. (Level II-2) (Pubitemid 36288497)
60. Sexually transmitted diseases treatment guidelines, 2006. Centers for Disease Control and Prevention. MMWR Recomm Rep 2006;55(RR-11):1-94. (Level III)
61. Anderson J. Gynecologic care and concerns in the HIVpositive woman. Adv Stud Med 2005;5:403-10. (Level III) (Pubitemid 41407389)
62. Vazquez JA, Peng G, Sobel JD, Steele-Moore L, Schuman P, Holloway W, et al. Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis. Clin Infect Dis 2001;33:1069-75. (Level I) (Pubitemid 32907112)
63. Anderson BL, Cu-Uvin S. Determinants of HIV shedding in the lower genital tract of women. Curr Infect Dis Rep 2008;10:505-11. (Level III)
64. Mcclelland RS, Wang CC, Mandaliya K, Overbaugh J, Reiner MT, Panteleeff DD, et al. Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS 2001;15:105-10. (Level III) (Pubitemid 32055785)
65. Cu-Uvin S, Hogan JW, Warren D, Klein RS, Peipert J, Schuman P, et al. Prevalence of lower genital tract infections among human immunodeficiency virus (HIV) - seropositive and high-risk HIV-seronegative women. HIV Epidemiology Research Study Group. Clin Infect Dis 1999;29:1145-50. (Level II-3) (Pubitemid 30265631)
66. Cu-Uvin S, Ko H, Jamieson DJ, Hogan JW, Schuman P, Anderson J, et al. Prevalence, incidence, and persistence or recurrence of trichomoniasis among human immunodeficiency virus (HIV)-positive women and among HIV-negative women at high risk for HIV infection. HIV Epidemiology Research Study (HERS) Group. Clin Infect Dis 2002;34:1406-11. (Level II-3) (Pubitemid 34507952)
67. Mugo NR, Kiehlbauch JA, Nguti R, Meier A, Gichuhi JW, Stamm WE, et al. Effect of human immunodeficiency virus-1 infection on treatment outcome of acute salpingitis. Obstet Gynecol 2006;107:807-12. (Level II-2)
68. Irwin KL, Moorman AC, O'Sullivan MJ, Sperling R, Koestler ME, Soto I, et al. Influence of human immunodeficiency virus infection on pelvic inflammatory disease. Obstet Gynecol 2000;95:525-34. (Level II-2) (Pubitemid 30139571)
69. Barbosa C, Macasaet M, Brockmann S, Sierra MF, Xia Z, Duerr A. Pelvic inflammatory disease and human immunodeficiency virus infection. Obstet Gynecol 1997;89:65-70. (Level II-3) (Pubitemid 27024469)
70. Rompalo AM, Joesoef MR, O'Donnell JA, Augenbraun M, Brady W, Radolf JD, et al. Clinical manifestations of early syphilis by HIV status and gender: results of the syphilis and HIV study. Syphilis and HIV Study Group. Sex Transm Dis 2001;28:158-65. (Level II-3) (Pubitemid 32194971)
71. Long CM, Klausner JD, Leon S, Jones FR, Giron M, Cuadros J, et al. Syphilis treatment and HIV infection in a population-based study of persons at high risk for sexually transmitted disease/HIV infection in Lima, Peru. NIMH Collaborative HIV/STD Prevention Trial Group. Sex Transm Dis 2006;33:151-5. (Level II-3) (Pubitemid 43790823)
72. Ghanem KG, Erbelding EJ, Wiener ZS, Rompalo AM. Serological response to syphilis treatment in HIVpositive and HIV-negative patients attending sexually transmitted diseases clinics. Sex Transm Infect 2007;83:97-101. (Level II-3) (Pubitemid 46713595)
73. Manavi K, McMillan A. The outcome of treatment of early latent syphilis and syphilis with undetermined duration in HIV-infected and HIV-uninfected patients. Int J STD AIDS 2007;18:814-8. (Level II-3) (Pubitemid 351738858)
74. Rolfs RT, Joesoef MR, Hendershot EF, Rompalo AM, Augenbraun MH, Chiu M, et al. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group. N Engl J Med 1997;337:307-14. (Level I) (Pubitemid 27318992)
75. Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006;296:964-73. (Level II-3) (Pubitemid 44285373)
76. Aumakhan B, Gaydos CA, Quinn TC, Beyrer C, Benning L, Minkoff H, et al. Clinical reactivations of herpes simplex virus type 2 infection and human immunodeficiency virus disease progression markers. PLoS One 2010;5:e9973. (Level II-2)
77. Posavad CM, Wald A, Kuntz S, Huang ML, Selke S, Krantz E, et al. Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy. J Infect Dis 2004;190:693-6. (Level II-3) (Pubitemid 39049997)
78. Ameli N, Bacchetti P, Morrow RA, Hessol NA, Wilkin T, Young M, et al. Herpes simplex virus infection in women in the WIHS: epidemiology and effect of antiretroviral therapy on clinical manifestations. AIDS 2006;20:1051-8. (Level II-2)
79. Delany S, Mlaba N, Clayton T, Akpomiemie G, Capovilla A, Legoff J, et al. Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS 2009;23:461-9. (Level I)
80. Dunne EF, Whitehead S, Sternberg M, Thepamnuay S, Leelawiwat W, McNicholl JM, et al. Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV-and HSV-2-infected women, Chiang Rai, Thailand. J Acquir Immune Defic Syndr 2008;49:77-83. (Level II-3)
81. Nagot N, Ouedraogo A, Foulongne V, Konate I, Weiss HA, Vergne L, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. ANRS 1285 Study Group. N Engl J Med 2007;356:790-9. (Level I) (Pubitemid 46294611)
82. Ouedraogo A, Nagot N, Vergne L, Konate I, Weiss HA, Defer MC, et al. Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial. AIDS 2006;20:2305-13. (Level I) (Pubitemid 44789532)
83. Conant MA, Schacker TW, Murphy RL, Gold J, Crutchfield LT, Crooks RJ. Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. International Valaciclovir HSV Study Group. Int J STD AIDS 2002;13:12-21. (Level I) (Pubitemid 34032997)
84. DeJesus E, Wald A, Warren T, Schacker TW, Trottier S, Shahmanesh M, et al. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. Valacyclovir International HSV Study Group [published erratum appears in: J Infect Dis 2003;188:1404]. J Infect Dis 2003;188:1009-16. (Level I) (Pubitemid 37268251)
85. Silverberg MJ, Ahdieh L, Munoz A, Anastos K, Burk RD, Cu-Uvin S, et al. The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts. Sex Transm Dis 2002;29:427-35. (Level II-3) (Pubitemid 34851777)
86. De Panfilis G, Melzani G, Mori G, Ghidini A, Graifemberghi S. Relapses after treatment of external genital warts are more frequent in HIV-positive patients than in HIV-negative controls. Sex Transm Dis 2002;29:121-5. (Level II-3) (Pubitemid 34219624)
87. Clark RA, Mulligan K, Stamenovic E, Chang B, Watts H, Andersen J, et al. Frequency of anovulation and early menopause among women enrolled in selected adult AIDS clinical trials group studies. J Infect Dis 2001;184:1325-7. (Level II-3) (Pubitemid 33055579)
88. Chirgwin KD, Feldman J, Muneyyirci-Delale O, Landesman S, Minkoff H. Menstrual function in human immunodeficiency virus-infected women without acquired immunodeficiency syndrome. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12:489-94. (Level III) (Pubitemid 26274939)
89. Massad LS, Evans CT, Minkoff H, Watts DH, Greenblatt RM, Levine AM, et al. Effects of HIV infection and its treatment on self-reported menstrual abnormalities in women. J Womens Health 2006;15:591-8. (Level II-3) (Pubitemid 44082668)
90. Harlow SD, Schuman P, Cohen M, Ohmit SE, Cu-Uvin S, Lin X, et al. Effect of HIV infection on menstrual cycle length. J Acquir Immune Defic Syndr 2000;24:68-75. (Level II-2) (Pubitemid 30447809)
91. Harlow SD, Cohen M, Ohmit SE, Schuman P, Cu-Uvin S, Lin X, et al. Substance use and psychotherapeutic medications: a likely contributor to menstrual disorders in women who are seropositive for human immunodeficiency virus. Am J Obstet Gynecol 2003;188:881-6. (Level II-2) (Pubitemid 36530033)
92. Kojic EM, Wang CC, Cu-Uvin S. HIV and menopause: a review. J Womens Health 2007;16:1402-11. (Level III) (Pubitemid 350233097)
93. Fan MD, Maslow BS, Santoro N, Schoenbaum E. HIV and the menopause. Menopause Int 2008;14:163-8. (Level III)
94. Schoenbaum EE, Hartel D, Lo Y, Howard AA, Floris-Moore M, Arnsten JH, et al. HIV infection, drug use, and onset of natural menopause. Clin Infect Dis 2005;41:1517-24. (Level II-2) (Pubitemid 41579999)
95. Cejtin HE, Kalinowski A, Bacchetti P, Taylor RN, Watts DH, Kim S, et al. Effects of human immunodeficiency virus on protracted amenorrhea and ovarian dysfunction. Obstet Gynecol 2006;108:1423-31. (Level II-2) (Pubitemid 44901017)
96. Conde DM, Silva ET, Amaral WN, Finotti MF, Ferreira RG, Costa-Paiva L, et al. HIV, reproductive aging, and health implications in women: a literature review. Menopause 2009;16:199-213. (Level III)
97. Prior J, Burdge D, Maan E, Milner R, Hankins C, Klein M, et al. Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study. Osteoporos Int 2007;18:1345-53. (Level II-2) (Pubitemid 47389474)
98. Negredo E, Martinez E, Cinquegrana D, Estany C, Clotet B. Therapeutic management of bone demineralization in the HIV-infected population. AIDS 2007;21:657-63. (Level III) (Pubitemid 46568622)
99. Weller SC, Davis-Beaty K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database of Systematic Reviews 2002, Issue 1. Art. No.: CD003255. DOI: 10.1002/14651858. CD003255. (Level III)
100. Minnis AM, Padian NS. Effectiveness of female controlled barrier methods in preventing sexually transmitted infections and HIV: current evidence and future research directions. Sex Transm Infect 2005;81:193-200. (Level III) (Pubitemid 40835042)
101. Drew WL, Blair M, Miner RC, Conant M. Evaluation of the virus permeability of a new condom for women. Sex Transm Dis 1990;17:110-2. (Level III) (Pubitemid 20224336)
102. French PP, Latka M, Gollub EL, Rogers C, Hoover DR, Stein ZA. Use-effectiveness of the female versus male condom in preventing sexually transmitted disease in women. Sex Transm Dis 2003;30:433-9. (Level II-1) (Pubitemid 36605493)
103. Wilkinson D, Tholandi M, Ramjee G, Rutherford GW. Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomised controlled trials including more than 5000 women. Lancet Infect Dis 2002;2:613-7. (Meta-analysis)
104. Baeten JM, Overbaugh J. Measuring the infectiousness of persons with HIV-1: opportunities for preventing sexual HIV-1 transmission. Curr HIV Res 2003;1:69-86. (Level III)
105. Castilla J, Del Romero J, Hernando V, Marincovich B, Garcia S, Rodriguez C. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 2005;40:96-101. (Level II-3) (Pubitemid 41233212)
106. Incorporating HIV prevention into the medical care of persons living with HIV. Recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Centers for Disease Control and Prevention (CDC); Health Resources and Services Administration; National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America [published erratum appears in MMWR Morb Mortal Wkly Rep 2004;53:744]. MMWR Recomm Rep 2003;52(RR-12):1-24. (Level III)
107. Panlilio AL, Cardo DM, Grohskopf LA, Heneine W, Ross CS. Updated U. S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. U. S. Public Health Service. MMWR Recomm Rep 2005;54(RR-9):1-17. (Level III)
108. Wingood GM, DiClemente RJ, Mikhail I, Lang DL, McCree DH, Davies SL, et al. A randomized controlled trial to reduce HIV transmission risk behaviors and sexually transmitted diseases among women living with HIV: The WiLLOW Program. J Acquir Immune Defic Syndr 2004;37(suppl 2):S58-67. (Level I)
109. Kamb ML, Fishbein M, Douglas JM Jr, Rhodes F, Rogers J, Bolan G, et al. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT Study Group. JAMA 1998;280:1161-7. (Level I) (Pubitemid 28457806)
110. Richardson BA, Otieno PA, Mbori-Ngacha D, Overbaugh J, Farquhar C, John-Stewart GC. Hormonal contraception and HIV-1 disease progression among postpartum Kenyan women. AIDS 2007;21:749-53. (Level II-3) (Pubitemid 46568632)
111. Cejtin HE, Jacobson L, Springer G, Watts DH, Levine A, Greenblatt R, et al. Effect of hormonal contraceptive use on plasma HIV-1-RNA levels among HIV-infected women. AIDS 2003;17:1702-4. (Level III) (Pubitemid 36951695)
112. El-Ibiary SY, Cocohoba JM. Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives. Eur J Contracept Reprod Health Care 2008;13:123-32. (Level III) (Pubitemid 352000659)
113. Farr S, Folger SG, Paulen M, Tepper N, Whiteman M, Zapata L, et al. U S. Medical eligibility criteria for contraceptive use, 2010: adapted from the World Health Organization Medical Eligibility Criteria for Contraceptive Use, 4th edition. Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion; Centers for Disease Control and Prevention (CDC). MMWR Recomm Rep 2010;59(RR-4):1-86. (Level III)
114. Sekar VJ, Lefebvre E, Guzman SS, Felicione E, De Pauw M, Vangeneugden T, et al. Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women. Antivir Ther 2008;13:563-9. (Level II-3) (Pubitemid 352016719)
115. Mildvan D, Yarrish R, Marshak A, Hutman HW, McDonough M, Lamson M, et al. Pharmacokinetic interaction between nevirapine and ethinyl estradiol/ norethindrone when administered concurrently to HIV-infected women. J Acquir Immune Defic Syndr 2002;29:471-7. (Level III) (Pubitemid 34456338)
116. Nanda K, Amaral E, Hays M, Viscola MA, Mehta N, Bahamondes L. Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy. Fertil Steril 2008;90:965-71. (Level II-2)
117. Watts DH, Park JG, Cohn SE, Yu S, Hitti J, Stek A, et al. Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. Contraception 2008;77:84-90. (Level III)
118. Stringer EM, Kaseba C, Levy J, Sinkala M, Goldenberg RL, Chi BH, et al. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol 2007;197:144.e1-144.e8. (Level I)
119. Morrison CS, Sekadde-Kigondu C, Sinei SK, Weiner DH, Kwok C, Kokonya D. Is the intrauterine device appropriate contraception for HIV-1-infected women? BJOG 2001;108:784-90. (Level II-2) (Pubitemid 32695308)
120. Richardson BA, Morrison CS, Sekadde-Kigondu C, Sinei SK, Overbaugh J, Panteleeff DD, et al. Effect of intrauterine device use on cervical shedding of HIV-1 DNA. AIDS 1999;13:2091-7. (Level II-3) (Pubitemid 29509586)
121. Lehtovirta P, Paavonen J, Heikinheimo O. Experience with the levonorgestrel-releasing intrauterine system among HIV-infected women. Contraception 2007;75:37-9. (Level III) (Pubitemid 44854865)
122. Heikinheimo O, Lehtovirta P, Suni J, Paavonen J. The levonorgestrel- releasing intrauterine system (LNG-IUS) in HIV-infected women-effects on bleeding patterns, ovarian function and genital shedding of HIV. Hum Reprod 2006;21:2857-61. (Level III) (Pubitemid 44566998)
123. Cates W Jr, Steiner MJ. Dual protection against unintended pregnancy and sexually transmitted infections: what is the best contraceptive approach? Sex Transm Dis 2002;29:168-74. (Level III) (Pubitemid 34219630)
124. Stanwood NL, Cohn SE, Heiser JR, Pugliese M. Contraception and fertility plans in a cohort of HIVpositive women in care. Contraception 2007;75:294-8. (Level III) (Pubitemid 46389617)
125. Sharma A, Feldman JG, Golub ET, Schmidt J, Silver S, Robison E, et al. Live birth patterns among human immunodeficiency virus-infected women before and after the availability of highly active antiretroviral therapy. Am J Obstet Gynecol 2007;196:541.e1-541.e6. (Level II-3)
126. Recommended adult immunization schedule-United States, 2010. Centers for Disease Control and Prevention. MMWR 2010;59(1). Available at: http://www.cdc.gov/mmwr/PDF/wk/mm5901-Immunization.pdf. Retrieved July 9, 2010.
127. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Bethesda (MD): Department of Health and Human Services; 2010 Available at: http://aidsinfo.nih.gov/Content Files/PerinatalGL.pdf. Retrieved June 17, 2010. (Level III)
128. American College of Obstetricians and Gynecologists. Scheduled cesarean delivery and the prevention of vertical transmission of HIV infection. ACOG Committee Opinion 234. Washington, DC: ACOG; 2000.
129. Semprini AE, Levi-Setti P, Bozzo M, Ravizza M, Taglioretti A, Sulpizio P, et al. Insemination of HIVnegative women with processed semen of HIV-positive partners. Lancet 1992;340:1317-9. (Level III)
130. Mandelbrot L, Heard I, Henrion-Geant E, Henrion R. Natural conception in HIV-negative women with HIVinfected partners. Lancet 1997;349:850-1. (Level III) (Pubitemid 27129219)
131. Barreiro P, del Romero J, Leal M, Hernando V, Asencio R, de Mendoza C, et al. Natural pregnancies in HIVserodiscordant couples receiving successful antiretroviral therapy. Spanish HIV-Discordant Study Group. J Acquir Immune Defic Syndr 2006;43:324-6. (Level III) (Pubitemid 44674013)
132. Gilling-Smith C, Nicopoullos JD, Semprini AE, Frodsham LC. HIV and reproductive care-a review of current practice. BJOG 2006;113:869-78. (Level III) (Pubitemid 44086910)
133. Savasi V, Ferrazzi E, Lanzani C, Oneta M, Parrilla B, Persico T. Safety of sperm washing and ART outcome in 741 HIV-1-serodiscordant couples. Hum Reprod 2007;22:772-7. (Level II-3)
134. Guidelines for reducing the risk of viral transmission during fertility treatment. Practice Committee of the American Society for Reproductive Medicine. Fertil Steril 2006;86:S11-7. (Level III)
135. Stanitis JA, Grow DR, Wiczyk H. Fertility services for human immunodeficiency virus-positive patients: provider policy, practice, and perspectives. Fertil Steril 2008;89:1154-8. (Level III) (Pubitemid 351681891)
136. HIV-1 infection and artificial insemination with processed semen. Centers for Disease Control (CDC). MMWR Morb Mortal Wkly Rep 1990;39:249, 255-6. (Level III)
137. Bujan L, Hollander L, Coudert M, Gilling-Smith C, Vucetich A, Guibert J, et al. Safety and efficacy of sperm washing in HIV-1-serodiscordant couples where the male is infected: results from the European CREAThE network. CREAThE network. AIDS 2007;21:1909-14. (Level II-2) (Pubitemid 47329767)